Brand-name drug prices soaring

patents expire, while taking advantage of the fact that last year's healthcare reform bill did not cap drug prices. According to MarketScan, payments for Pfizer Inc's Lipitor rose 11.4 percent last year, compared with 5 percent annually from 2005 to...